How does abrysvo protect infants?

How does Abrysvo protect infants?

Abrysvo is a maternal vaccine that works by prompting a pregnant woman’s immune system to produce antibodies against respiratory syncytial virus (RSV). These antibodies pass through the placenta into the fetus and remain in the newborn’s blood after birth, providing passive protection until the infant develops its own active immunity.

What happens if the mother receives the vaccine too late in pregnancy?

If vaccination occurs after 36 weeks of gestation, antibody transfer across the placenta is reduced. The manufacturer recommends administration between 32 and 36 weeks to maximize antibody levels in the newborn.

Why are companies challenging this patent?

DrugPatentWatch.com reports that generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) and paragraph IV certifications against Abrysvo’s patents, indicating active litigation over the vaccine’s intellectual property rights.

How does Abrysvo compare with other RSV vaccines?

Abrysvo is one of two licensed maternal RSV vaccines. It differs from Beyfortus (nirsevimab), a monoclonal antibody given directly to the infant at birth, in that it relies on transplacental antibody transfer rather than direct administration.

When does exclusivity expire?

According to DrugPatentWatch.com, Abrysvo’s regulatory exclusivity period is scheduled to expire in 2031.